OUTLOOK THERAPEUTICS INC (OTLK) - Total Liabilities

Latest as of September 2025: $50.77 Trillion USD

Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has total liabilities worth $50.77 Trillion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does OUTLOOK THERAPEUTICS INC generate cash to assess how effectively this company generates cash.

OUTLOOK THERAPEUTICS INC - Total Liabilities Trend (2014–2025)

This chart illustrates how OUTLOOK THERAPEUTICS INC's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are OUTLOOK THERAPEUTICS INC's assets to evaluate the company's liquid asset resilience ratio.

OUTLOOK THERAPEUTICS INC Competitors by Total Liabilities

The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their total liabilities.

Company Country Total Liabilities
Daesung Microbiological Labs. Co. Ltd
KQ:036480
Korea ₩22.65 Billion
Excelsior Capital Ltd
AU:ECL
Australia AU$1.37 Million
CEL-SCI Corp
NYSE MKT:CVM
USA $11.76 Million
Ion Video Ltd
AU:IOV
Australia AU$2.81 Million
Dpi Holdings Berhad
KLSE:0205
Malaysia RM41.60 Million
Ba Ria Thermal Power JSC
VN:BTP
Vietnam ₫147.46 Billion
Ashford Hospitality Trust Inc
NYSE:AHT
USA $3.21 Billion
Carboclor
BA:CARC
Argentina AR$9.08 Billion

Liability Composition Analysis (2014–2025)

This chart breaks down OUTLOOK THERAPEUTICS INC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see OTLK market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.38 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -1577369.79 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 2.73 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how OUTLOOK THERAPEUTICS INC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for OUTLOOK THERAPEUTICS INC (2014–2025)

The table below shows the annual total liabilities of OUTLOOK THERAPEUTICS INC from 2014 to 2025.

Year Total Liabilities Change
2025-09-30 $50.77 Trillion +49825230.14%
2024-09-30 $101.90 Million +118.02%
2023-09-30 $46.74 Million +136.16%
2022-09-30 $19.79 Million +8.72%
2021-09-30 $18.20 Million +7.67%
2020-09-30 $16.91 Million -39.41%
2019-09-30 $27.90 Million -35.25%
2018-09-30 $43.09 Million -16.26%
2017-09-30 $51.46 Million +78.03%
2016-09-30 $28.91 Million -17.77%
2015-09-30 $35.15 Million -45.30%
2014-09-30 $64.26 Million --

About OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK USA Biotechnology
Market Cap
$19.26 Million
Market Cap Rank
#25133 Global
#5095 in USA
Share Price
$0.26
Change (1 day)
+4.80%
52-Week Range
$0.20 - $2.97
All Time High
$867.20
About

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more